An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC)
Keywords: Small cell lung cancer; Plk-1 inhibition; Polo-like kinase; BI 2536;